Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Amgen Inc. Stories

2009-10-16 08:31:00

CHICAGO, Oct. 16 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for COP, AMGN, NFLX, LPL, and PAG. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/101609B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: ConocoPhillips (NYSE: COP), Amgen Inc. (Nasdaq: AMGN), Netflix, Inc. (Nasdaq: NFLX), LG Display Co., Ltd. (NYSE: LPL), and...

2009-09-14 06:45:00

MINNEAPOLIS and CHICAGO, Sept. 14 /PRNewswire/ -- Sunlight Research((TM)) - The Source for Patent Analysis (www.sunlightresearch.com) today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio. The Report analyzes the patent claims coverage of 38 US patents owned or controlled by Amgen (Nasdaq: AMGN), and explains how those patents do or do not cover the corresponding technology used in their commercial product Epogen. The technology...

2009-09-13 13:47:00

DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). "These data enhance our understanding of why many women discontinue treatment with current osteoporosis therapies,...

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...

2009-09-08 09:11:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Prescription Drugs http://www.reportlinker.com/p0131233/Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2009-09-08 08:31:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Nanomedicine http://www.reportlinker.com/p0131218/Nanomedicine.html This report analyzes the Global Market for Nanomedicine in Millions of US$ by the following Application Areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Others. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 263 companies...

2009-09-02 11:00:00

NEW YORK, Sept. 2 /PRNewswire/ -- Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to severe plaque psoriasis who have not allowed the condition to inhibit their personal style. Winners of the Addressing Psoriasis(TM) contest are...

2009-08-13 17:37:00

THOUSAND OAKS, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast...

2009-08-13 06:52:00

THOUSAND OAKS, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer patients undergoing hormone ablation at a meeting with the U.S. Food and Drug Administration's (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). "There remains...